Showing results (1621-1630 of 1,751) with videos related to
Sort By:
Pageof 176
Annals of Hematology|May 10, 2021
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the USFaith Davies, Robert Rifkin, Caitlin Costello, et al.Frontiers in Medicine|September 19, 2022
Frequency and gender differences in the use of professional home care in late life. Findings from three German old-age cohortsElżbieta W Buczak-Stec, André Hajek, Alexander Pabst, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple MyelomaAntonio Palumbo, Francesca Gay, Federica Cavallo, et al.Ejhaem|July 18, 2022
Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomibPaul G Richardson, Arnon Nagler, Dina Ben-Yehuda, et al.The Journal of Nutrition|September 22, 2007
Telephone counseling helps maintain long-term adherence to a high-vegetable dietary patternJohn P Pierce, Vicky A Newman, Loki Natarajan, et al.Haematologica|February 6, 2014
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myelomaMonika Engelhardt, Evangelos Terpos, Martina Kleber, et al.The Lancet. Oncology|February 15, 2014
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient dataAntonio Palumbo, Sara Bringhen, Shaji K Kumar, et al.JAMA Oncology|February 10, 2022
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical TrialNicholas J Vogelzang, Tomasz M Beer, Winald Gerritsen, et al.Blood Cancer Journal|June 4, 2021
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trialStefania Oliva, Davine Hofste Op Bruinink, Lucie Rihova, et al.The New England Journal of Medicine|May 11, 2012
Continuous lenalidomide treatment for newly diagnosed multiple myelomaAntonio Palumbo, Roman Hajek, Michel Delforge, et al.Pageof 176